The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

Please provide your email address to receive an email when new articles are posted on . Perioperative combination therapy using a long-acting muscarinic antagonist and long-acting beta agonist may be ...

The researchers noted that their findings highlight the need to understand the challenges in delivering evidence-based care for chronic obstructive pulmonary disease (COPD). Patients who live in rural ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

• LAMA/LABA therapy now an essential cornerstone for COPD treatment across the spectrum of people with COPD in GOLD groups B-D 1 INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim welcomes the ...

Chronic obstructive pulmonary disease (COPD) treatments involving inhaled corticosteroids (ICSs) were associated with a greater risk for fractures, a meta-analysis of several dozen randomized trials ...

Leah J. Witt, MD: Hello. I'm Dr Leah Witt. Welcome to season one of Medscape InDiscussion, chronic obstructive pulmonary disease (COPD) podcast series. Today we're talking medications, especially ...

Chronic obstructive pulmonary disease (COPD) is defined by airway obstruction and alveolar damage caused by exposure to noxious air particles. The physiologic results include varying degrees of ...

AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...

LA JOLLA, Calif., October 07, 2025--(BUSINESS WIRE)--AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic ...